Ravi S. Narayan

732 total citations
12 papers, 502 citations indexed

About

Ravi S. Narayan is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Ravi S. Narayan has authored 12 papers receiving a total of 502 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Genetics and 3 papers in Oncology. Recurrent topics in Ravi S. Narayan's work include Glioma Diagnosis and Treatment (5 papers), Cancer therapeutics and mechanisms (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Ravi S. Narayan is often cited by papers focused on Glioma Diagnosis and Treatment (5 papers), Cancer therapeutics and mechanisms (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Ravi S. Narayan collaborates with scholars based in Netherlands, United States and Spain. Ravi S. Narayan's co-authors include Godefridus J. Peters, Jaime Imitola, Santosh Kesari, Anna M. Krichevsky, Robert M. Stephens, Thomas Würdinger, Johanna M. Niers, Christine Esau, Galina Gabriely and Keith L. Ligon and has published in prestigious journals such as Cancer Research, Oncotarget and Molecular Cancer Therapeutics.

In The Last Decade

Ravi S. Narayan

11 papers receiving 497 citations

Peers

Countries citing papers authored by Ravi S. Narayan

Since Specialization

Citations

This map shows the geographic impact of Ravi S. Narayan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ravi S. Narayan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ravi S. Narayan more than expected).

Fields of papers citing papers by Ravi S. Narayan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ravi S. Narayan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ravi S. Narayan. The network helps show where Ravi S. Narayan may publish in the future.

Co-authorship network of co-authors of Ravi S. Narayan

This figure shows the co-authorship network connecting the top 25 collaborators of Ravi S. Narayan. A scholar is included among the top collaborators of Ravi S. Narayan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ravi S. Narayan. Ravi S. Narayan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype 2025 ·Molecular Cancer Therapeutics ·(unknown), (unknown), Ravi S. Narayan, (unknown), Sander R. Piersma, (unknown), Thang V. Pham, David P. Noske, W. Peter Vandertop, Connie R. Jiménez, Bart A. Westerman	0
2	Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma 2019 ·Journal of Neuro-Oncology ·(unknown), Robin M. de Kruijff, Astrid J.G.M. van der Meer, (unknown), Susanne M. A. van der Pol, (unknown), (unknown), Ravi S. Narayan, Helga E. de Vries, Ben J. Slotman, Antonia G. Denkova, Peter Sminia	19
3	WINDOW consortium: A path towards increased therapy efficacy against glioblastoma 2018 ·Drug Resistance Updates ·(unknown), (unknown), Fredrik Svensson, Ravi S. Narayan, (unknown), Aslι Küçükosmanoğlu, Emmanouil Metzakopian, Colin Watts, David Bailey, Tom Würdinger, Bart A. Westerman	16
4	Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma 2017 ·Molecular Cancer Therapeutics ·Ravi S. Narayan, (unknown), (unknown), (unknown), Tonny Lagerweij, (unknown), (unknown), Jaap van den Berg, Ben J. Slotman, Tom Würdinger, Daphne A. Haas‐Kogan, Lukas J.A. Stalpers, Brigitta G. Baumert, Bart A. Westerman, Jan Theys, Peter Sminia	19
5	The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures 2017 ·BMC Cancer ·Ravi S. Narayan, (unknown), (unknown), (unknown), Lukas J.A. Stalpers, Brigitta G. Baumert, Ben J. Slotman, Bart A. Westerman, Godefridus J. Peters, Peter Sminia	53
6	Role of Akt signaling in resistance to DNA-targeted therapy 2016 ·World Journal of Clinical Oncology ·Abolfazl Avan, Ravi S. Narayan, Elisa Giovannetti, Godefridus J. Peters	57
7	NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor 2015 ·Oncotarget ·Elena Galvani, Jing Sun, Leticia G. León, Rocco Sciarrillo, Ravi S. Narayan, Robert Tjin Tham Sjin, Kwangho Lee, Kadoaki Ohashi, Daniëlle A.M. Heideman, Roberta Alfieri, Guus J.J.E. Heynen, René Bernards, Egbert F. Smit, William Pao, Godefridus J. Peters, Elisa Giovannetti	26
8	Abstract 4914: AKT- and ERK signaling inhibition does not sensitize GBM cells to chemo-/radiation in vitro 2014 ·Cancer Research ·Ravi S. Narayan, (unknown), Jaap van den Berg, Lukas J.A. Stalpers, Brigitta G. Baumert, Ben J. Slotman, Peter Sminia	1
9	Targeting the Akt-pathway to Improve Radiosensitivity in Glioblastoma 2012 ·Current Pharmaceutical Design ·Ravi S. Narayan, (unknown), Lukas J.A. Stalpers, Brigitta G. Baumert, Peter Sminia	1
10	Targeting the Akt-pathway to Improve Radiosensitivity in Glioblastoma 2012 ·Current Pharmaceutical Design ·Ravi S. Narayan, (unknown), Lukas J.A. Stalpers, Brigitta G. Baumert, Peter Sminia	22
11	Human Glioma Growth Is Controlled by MicroRNA-10b 2011 ·Cancer Research ·Galina Gabriely, Ming Yi, Ravi S. Narayan, Johanna M. Niers, Thomas Würdinger, Jaime Imitola, Keith L. Ligon, Santosh Kesari, Christine Esau, Robert M. Stephens, Bakhos A. Tannous, Anna M. Krichevsky	245
12	The cytosolic β-glucosidase GBA3 does not influence type 1 Gaucher disease manifestation 2010 ·Blood Cells Molecules and Diseases ·Nick Dekker, Tineke Voorn-Brouwer, Marri Verhoek, Tom Wennekes, Ravi S. Narayan, Dave Speijer, Carla E. M. Hollak, Herman S. Overkleeft, Rolf G. Boot, Johannes M. F. G. Aerts	43

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact